Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial

Prolonged treatment of tuberculosis (TB) often leads to poor compliance, default and relapse, converting primary TB patients into category II TB (Cat IITB) cases, many of whom may convert to multi-drug resistant TB (MDR-TB). We have evaluated the immunotherapeutic potential of Mycobacterium indicus...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Sharma, Surendra K., Katoch, Kiran, Sarin, Rohit, Balambal, Raman, Kumar Jain, Nirmal, Patel, Naresh, Murthy, Kolluri J. R., Singla, Neeta, Saha, P. K., Khanna, Ashwani, Singh, Urvashi, Kumar, Sanjiv, Sengupta, A., Banavaliker, J. N., Chauhan, D. S., Sachan, Shailendra, Wasim, Mohammad, Tripathi, Sanjay, Dutt, Nilesh, Jain, Nitin, Joshi, Nalin, Penmesta, Sita Ram Raju, Gaddam, Sumanlatha, Gupta, Sanjay, Khamar, Bakulesh, Dey, Bindu, Mitra, Dipendra K., Arora, Sunil K., Bhaskar, Sangeeta, Rani, Rajni
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469738/
https://ncbi.nlm.nih.gov/pubmed/28611374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-03514-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares